Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

1.18
+0.05004.42%
Post-market: 1.180.00000.00%16:30 EDT
Volume:599.60K
Turnover:704.53K
Market Cap:83.93M
PE:-0.60
High:1.19
Open:1.15
Low:1.15
Close:1.13
Loading ...

Press Release: Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Dow Jones
·
01 Apr

Insiders' US$1.26m Investments In Red Following Ventyx Biosciences' US$11m Dip In Market Value

Simply Wall St.
·
31 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)

TIPRANKS
·
07 Mar

Ventyx Biosciences Reports 2024 Financial Results and Progress

TIPRANKS
·
05 Mar

Analysts’ Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)

TIPRANKS
·
02 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)

TIPRANKS
·
02 Mar

Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges

TIPRANKS
·
01 Mar

Ventyx Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Mar

LifeSci Capital Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
01 Mar

H.C. Wainwright Sticks to Their Hold Rating for Ventyx Biosciences (VTYX)

TIPRANKS
·
28 Feb

Ventyx Biosciences Q4 EPS $(0.41) Beats $(0.54) Estimate

Benzinga
·
28 Feb

BRIEF-Ventyx Biosciences Q4 EPS USD -0.41

Reuters
·
28 Feb

Press Release: Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Dow Jones
·
28 Feb

Ventyx Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
22 Feb

Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025

THOMSON REUTERS
·
18 Feb

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

GlobeNewswire
·
18 Feb

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Simply Wall St.
·
23 Jan

Ventyx Biosciences (VTYX) Gets a Hold from H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates

TIPRANKS
·
14 Jan